P/B
5,9
MeiraGTx
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
$1.3B
Market Cap • 9/18/2026
2018
(8 years)
Founded
2018
(8 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
3,2
P/EBITDA
6,5
P/OCF
93
P/FCF
121,6
P/E
14,2
BVPS
2,6
EPS
1,9
Market Cap
Market Cap
1,3B
EV
1,2B
EV/Revenue
3,1
EV/EBITDA
6,3
EV/EBIT
6,7
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-8,6%
Total Yield
-8,6%
Payout
0%
Retained Earnings
-701,8M
Profitability
Gross Margin
99,6%
EBITDA Margin
49,3%
EBIT Margin
46,3%
Net Margin
19,9%
D&A/EBITDA
0%
R&D/Revenue
38,5%
Capex/Revenue
0,8%
Capex/D&A
26,6%
Capex/OCF
23,5%
SBC/OCF
138,7%
% PPE
33,9%
% Goodwill
0%
ROE
72,2%
ROIC
104,6%
Growth
CAGR Revenue 5Y
84,5%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
3,8
Quick Ratio
2,9
Interest Coverage
1475%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!